Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cell cycle deregulation in B-cell lymphomas.

Margarita Sánchez-Beato1, Abel Sánchez-Aguilera, Miguel A Piris

  • 1Lymphoma Group, Molecular Pathology Program, Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain.

Blood
|October 24, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

DNA methylation-based classification of hematolymphoid neoplasms.

Blood advances·2026
Same author

Splice-site mutations in POU2AF1 are associated with B-cell lymphomagenesis and therapeutic response.

Scientific reports·2026
Same author

Ketone Bodies Are Potential Prognostic Biomarkers in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Results from the R2-GDP-GOTEL Trial.

Cancers·2025
Same author

Author Correction: Immune and stromal transcriptional patterns that influence the outcome of classic Hodgkin lymphoma.

Scientific reports·2024
Same author

Lymphoma Classifications, How to Develop a Future Unified Taxonomy.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2024
Same author

Generation and External Validation of a Histologic Transformation Risk Model for Patients with Follicular Lymphoma.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc·2024
Same journal

Fibrocytes drive JAK2V617F-mutated myelofibrosis: pitavastatin reverses marrow fibrosis and anemia.

Blood·2026
Same journal

Identifying steroid-refractory aGVHD before it happens.

Blood·2026
Same journal

ELISA-negative HIT: antibody recognition and relevance.

Blood·2026
Same journal

EBV and immunodeficiency: the odd couple drawn to the brain.

Blood·2026
Same journal

A bone to pick with ferric carboxymaltose.

Blood·2026
Same journal

A step toward streamlining HIT diagnosis.

Blood·2026
See all related articles

Cancer involves disrupted cell balance. Low-growth lymphomas inhibit apoptosis (cell death), while high-growth lymphomas enhance proliferation via oncogene deregulation, both leading to aggressive B-cell lymphomas.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • Cancer is characterized by a disruption in the balance between cell proliferation and cell death.
  • Human B-cell lymphomas are classified into low- and high-growth fraction types based on the underlying molecular mechanisms.
  • Low-growth lymphomas often inhibit apoptosis (programmed cell death), while high-growth lymphomas exhibit increased proliferation due to oncogene deregulation.

Purpose of the Study:

  • To review current knowledge on molecular alterations in B-cell lymphomas.
  • To emphasize the deregulation of cell cycle progression in lymphoma development.
  • To integrate information into a global model of B-cell lymphoma genesis and progression.

Main Methods:

  • Review of existing literature on molecular mechanisms in B-cell lymphomas.

Related Experiment Videos

  • Analysis of genetic alterations affecting apoptosis and cell cycle regulation.
  • Integration of pathway alterations to understand lymphoma progression.

    • Main Results:

    • Low-growth lymphomas (e.g., follicular lymphoma, MALT lymphoma) inhibit apoptosis through genetic events (BCL2, BCL10, API2/MLT1).
    • High-growth lymphomas (e.g., large B-cell lymphoma, Burkitt lymphoma) show enhanced proliferation due to oncogene deregulation (BCL6, c-myc).
    • Both types accumulate alterations in cell cycle regulators, including tumor suppressor genes (p16INK4a, p53, p27KIP1), contributing to aggressive behavior.

    Conclusions:

    • Disruption of cell proliferation and death pathways drives B-cell lymphoma development.
    • Specific molecular events characterize low- and high-growth fraction lymphomas.
    • Accumulation of genetic alterations, particularly in cell cycle regulation, leads to increased lymphoma aggressivity.